Quit Kit, LLC – Online Advisory Letter

Online Advisory Letter Reference #715029

September 10, 2025

Quit Kit, LLC
3304 Selwyn Farms Lane, Unit 3
Charlotte, NC 28209
info@tryquitkit.com
Phone # 718-974-8797

Dear Matthew von Boecklin:

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https://tryquitkit.com/ in August 2025 and has found that you take orders there for “Quit Kit” in morning, afternoon, and nighttime formulations. Various claims and statements made on your website and/or in other labeling establish that these products are drugs as defined in 21 U.S.C. § 321(g)(1)(B) because they are intended for the treatment, cure, mitigation, or prevention of disease. For example, your website recommends or suggests the use of “Quit Kit” to treat addiction to opioids. As explained further below, the intoduction of these products into interstate commerce for such uses violates the Federal Food, Drug, and Cosmetic Act.

These products are also new drugs as defined under 21 U.S.C. § 321(p) because they are not generally recognized as safe and effective for the uses recommended or suggested in their labeling. Before a new drug may be marketed or otherwise introduced into interstate commerce, it must be approved by FDA on the basis of scientific data demonstrating that the drug is safe and effective under the conditions of use in its labeling. See 21 U.S.C. §§ 355(a) and 331(d). Your drug products do not have FDA-approved applications as required by 21 U.S.C. § 355.

We advise you to review all materials through which you communicate to consumers the intended uses of your products, and to either submit a new drug application (NDA) for products intended for use in treating, curing, mitigating, diagnosing, or preventing a disease or, alternatively, remove all statements indicating that your products are intended for such uses. This would include reviewing your websites, product labels, catalogs, brochures, flyers, package inserts, audio and video, e-commerce and social media accounts you operate (e.g., Amazon, eBay, Facebook and X accounts), as well as any other promotional materials, and removing product claims, consumer testimonials, metatags, and anything else that states or implies that your products are useful in treating, curing, mitigating, diagnosing, or preventing diseases.

For more information on the kinds of claims that establish that a product is intended for use as a drug, please see 21 CFR 101.93(f)-(g) and https://www.fda.gov/food/food-labeling-nutrition/label-claims-conventional-foods-and-dietary-supplements.

Within 30 calendar days of the date of this letter, please correct the violations described in this letter and notify FDA, via electronic mail at FDAadvisory@fda.hhs.gov, that the violations have been corrected. Include the Online Advisory Letter Reference number (located in the upper right portion of this letter) in all your communications to FDA regarding this matter.

After 30 days from the date of this letter, if your website(s) or other labeling continue to demonstrate that your products are intended to treat, cure, mitigate, or prevent diseases, the name of your firm and this letter will be posted on the FDA webpage for products illegally marketed for serious diseases.

This letter is not intended to be an all-inclusive review of your website(s) or a list of all violations of law that exist in connection with your products, your website(s) and other product labeling, or at your facilities. FDA expects you to take the necessary steps to ensure that all your products comply with the laws and regulations enforced by FDA.

Sincerely,

Health Fraud Inspectorate Branch
Division of Field Enforcement
Office of Inspections and Investigations
U.S Food and Drug Administration
FDAAdvisory@fda.hhs.gov

STEPS TO CORRECT CITED VIOLATIONS

1. Within 30 calendar days of the date of this letter,
   1. Correct all violations described in the letter, and
   2. Notify FDA in writing of the corrections completed in response to this letter.
      1. Email this information to FDAadvisory@fda.hhs.gov.
      2. Include the Online Advisory Letter Reference number (located in the upper right portion of this letter) in all your communications to FDA.
2. After 30 calendar days, if you have not corrected the violations described in this letter, the name of your firm and this letter will be posted on FDA’s webpage, www.fda.gov/ICECI/EnforcementActions/AdvisoryLetters/default.htm.

Source